1 / 27

Plasma concentration

Pharmacologic administration curves after single opioid dose. IV: C max ~6 minutes. SQ: C max ~ 30 minutes. PO: C max ~ 60 minutes (oxymorphone ~ 30 minutes ). Plasma concentration. Time. Opioid infusionsDose escalation. PRN dosing interval based on time to C max:

isabella-jensen
Télécharger la présentation

Plasma concentration

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pharmacologic administration curves after single opioid dose IV: Cmax ~6 minutes SQ: Cmax ~ 30 minutes PO: Cmax ~ 60 minutes (oxymorphone ~ 30 minutes ) Plasma concentration Time

  2. Opioid infusionsDose escalation • PRN dosing interval based on time to Cmax: • 1 mg hydromorphone iv Q 10 minutes prn • 1 mg hydromorphone sq Q 15-30 minutes • Despite these efforts Fred continues to have uncontrolled pain. • How rapidly can you safely escalate his continuous infusion and his prn dose?

  3. Opioid infusionsDose escalation • Adjust bolus dose by up to 100% at least every 30-60 minutes until effective • Adjust infusion rate by up to 100% based on prn need every 12-24 hours

  4. The pain crisis • 40 year old man with rectal cancer • S/P abdominoperineal resection • Wound dehiscence • Hospitalized for > 100 days • Daily c/o severe pain • Prescribed 2 mg hydromorphone q 1 hour prn pain • Uncertain how much he had actually been receiving

  5. The pain crisis

  6. Methadone

  7. Methadone • Dual effect • Mu-opioid receptor antagonist (analgesia) • NMDA antagonist (prevention/reversal of opioid tolerance) • Variable equianalgesic ratios

  8. Methadone • 24 hr oral morphine • 0-30 mg • 31-99 mg • 100-299 mg • 300-499 mg • 500-999 mg • > 1000 mg • PO Morphine: Methadone ratio • 2:1 • 4:1 • 8;1 • 12:1 • 15:1 • 20:1

  9. Methadone • Dual affect • Mu-opioid receptor antagonist (analgesia) • NMDA antagonist (prevention/reversal of opioid tolerance) • Variable equianalgesic ratios • Variable metabolism • Half life 8 to 190 hours • Plethora of drug-drug interactions

  10. Methadone • Potent • Effective • Cheap • Complicated • Dangerous

  11. Fentanyl • IV:Transdermal =2:1 • Fentanyl IV: Morphine IV roughly 100:1 • Transdermal absorption dependent on fat stores

  12. Side effects • Constipation • Up to 80 % of patients • Requires stimulant laxatives • Does not abate with time • Counseling important • Nausea • Transient • Vestibular mediated • Responds to anticholinergic anti-emetics • Ondansetron is NOT an anticholinergic antiemetic • Educate patients

  13. Side effects • Pruritis • Transient, responds to antihistamines. • Histamine release is pharmacologic property of morphine • Often misinterpreted as allergic reaction • Urinary retention • Rare but potentially serious

  14. Side effects • Sedation • Especially with initiation or dose increase • Usually resolves • More common with elderly, high dose, polypharmacy • Responds to • Adjuvants/dose reduction • Opioid rotation • Stimulants • Marked sedation requires evaluation

  15. Neurotoxicity

  16. Opioid neurotoxicity • 55 yo old woman with breast cancer • Pain initially controlled on dilaudid 10 mg/hour • Over the past 10 days pain has worsened despite increase in dilaudid to 50 mg/hr. • Patient is anxious, restless. Complains of pain “all over” • Pain elicited by gently stroking arm • Occasional twitching of chest wall and leg noted.

  17. Opioid metabolism • Morphine is metabolized in the liver to: • Morphine-6 glucuronide (Active) • Morphine-3 glucuronide (Neuroexictory) • Excreted in the kidney • Morphine-3-glucuronide accumulates in renal failure, high dose and prolonged therapy, oliguria

  18. Opioid neurotoxicity • Increasing sensitivity to pain (hyperalgesia) • Worsening pain despite rapid opioid escalation • Pain becomes diffuse • Delirium, hallucinations • Allodynia, myoclonus, seizures

  19. Opioid neurotoxicity • Risk factors: • High dose • Morphine>hydromorphone>oxycodone, fentanyl, methadone • Renal failure • Oliguria • Can occur at any dose

  20. Opioid neurotoxicityManagement • Prevention, anticipation, early recognition • Assess urine output, magnesium level, electrolyte abnormalities • Hydration if otherwise appropriate • Opioid rotation at 25% equianalgesic dose • Add NMDA antagonist (ketamine or methadone) • Benzodiazepines/phenobarbital based on severity

  21. Opioid refractory pain

  22. Causes of opioid refractory pain • Rapid progression cancer • New source of pain • Abscess • Occult fracture • Bladder outlet obstruction • Pain refractory to opioids (Neuropathic pain, skin ulceration) • Opioid related • Malabsorption, • Drug diversion • Toxicity • Fear, existential or spiritual pain • Delirium

  23. Opioid refractory pain-Management • Opioid rotation or dose escalation • Use of adjuvants, non-opioids • NMDA antagonists (Ketamine and/or methadone) • Address spiritual and psychologic concerns • Non-pharmacologic treatments • Interventional modalities, radiation therapy if appropriate • Consideration of palliative sedation

  24. Barriers to pain relief • Clinician related • Health care system related • Patient related

  25. Patient related • Reluctance to report • “The good patient” • Fear of not receiving chemotherapy • Reluctance to treat • Fears of tolerance • Fear of addiction • Stigma • Meaning of pain • Side effects • “A tradeoff between managing the pain and managing the consequences of managing the pain”

  26. Supporting patient adherence • Normalize concerns • “Some patients worry about becoming addicted or the drug not working in the future when you need it. Are these of concern to you?” • Non-judgmental questioning: • “It must be really hard to take all these pills. How often, in the last week, have you found that you forget one or two?” • Educate and follow up on likely side effects

  27. “Pain is a multifaceted phenomenon involving not only a tissue damage response but also psychological, social, spiritual and existential domains. • (Nessa Coyle, JPSM, 2004)

More Related